Inclusion criteria
  1. Subjects with informed consent;
  2. 45-75 years of age;
  3. At least 6 years of education;
  4. AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) guidelines;
  5. Clinical Dementia Rating Scale (CDR)=1.0;
  6. Positive findings with amyloid PET imaging;
  7. On a stable dose of cholinesterase inhibitors (e.g. donepezil or rivastigmine) as defined as 6 consecutive weeks of treatment at an unchanging dose, and without any intentions to modify the dosage during the observation period.
Exclusion criteria
  1. Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis), poorly controlled migraines or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment;
  2. Contraindication for undergoing MRI or receiving tACS;
  3. Eczema or sensitive skin;
  4. Familial AD;
  5. Depression or other psychiatric disorders;
  6. Abnormal brain structural magnetic resonance imaging (MRI) scan, including hydrocephalus, stroke, structural lesions, etc. that would potentially confound the outcome;
  7. Severe cardiovascular/pulmonary disorders;
  8. Other conditions, in the investigator's opinion, might not be suitable for the study.